Answers are grounded in this paper and cite their sources.
GSK2256098 was well tolerated and resulted in an improved PFS6 rate in patients with recurrent or progressive NF2-mutated meningiomas, compared with historical controls. The criteria for promising activity were met, and FAK inhibition warrants further evaluation for this patient population.
No takes yet. Share an insight, caveat, or question.
Brastianos et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: